Lloyd Mitchell Segal - 12 Jan 2026 Form 4 Insider Report for Aktis Oncology, Inc. (AKTS)

Role
Director
Signature
/s/ Karen McCarthy, as Attorney-in-Fact
Issuer symbol
AKTS
Transactions as of
12 Jan 2026
Net transactions value
$0
Form type
4
Filing time
12 Jan 2026, 17:00:08 UTC
Previous filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Segal Lloyd Mitchell Director C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Karen McCarthy, as Attorney-in-Fact 12 Jan 2026 0001477123

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTS Common Stock Conversion of derivative security +19,631 19,631 12 Jan 2026 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTS Series A Redeemable Convertible Preferred Stock Conversion of derivative security $0 -50,000 -100% $0.000000 0 12 Jan 2026 Common Stock 13,142 See Footnote F2, F3
transaction AKTS Series B Redeemable Convertible Preferred Stock Conversion of derivative security $0 -24,687 -100% $0.000000 0 12 Jan 2026 Common Stock 6,489 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration.
F2 Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.
F3 The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock.